Navigation Links
CellCept(R) and a Reduced Level of CNI Shows Trend Towards Preservation of Kidney Function Versus a Standard-Dose CNI
Date:6/4/2008

TORONTO, June 4 /PRNewswire/ -- The 12-month results from a multicenter trial monitoring CellCept(R) (mycophenolate mofetil) in combination with calcineurin inhibitors (CNIs) in renal transplantation was presented today at the American Transplant Congress (ATC). The study results showed that a reduced level of CNI with a therapeutic monitored dose of CellCept is not inferior to that of a fixed dose of CellCept, and the standard-dose of CNI as it relates to biopsy-proven acute rejection (BPAR) and other end points.

The lower CNI dose regimen studied to avoid long-term side effects of chronic administration of CNI, facilitated a higher CellCept dosing without an overall increase in adverse events, and with a trend toward preservation of kidney function versus the standard-dose CNI regimens. As transplant patients are living longer, studies suggest that therapies such as CNIs can cause impairment of kidney function, damage to the blood vessels, and filtering capacity of the kidneys.

"The Opticept trial was designed to examine the impact of monitored CellCept dosing to enable a low dose CNI regimen with fewer complications and preservation of efficacy in preventing rejection," said Robert Gaston, M.D., lead investigator, University of Alabama at Birmingham, Birmingham, AL. "The 12-month study results are very encouraging and additional follow-up may provide insights into the long-term impact of these short-term findings."

About the Study

Opticept is a two-year open-label, prospective, randomized, multicenter study involving 720 single-organ renal allograft recipients administered either concentration-controlled CellCept and a reduced level of CNI, a concentration-controlled CellCept and the standard level of CNI, or a fixed-dose of CellCept and the standard level CNI.

Antibody induction and/or corticosteroids were administered according to center practice. Primary endpoints were the proportion of patients with treatment failure
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Final Results of the CellCept(R) Spare the Nephron (STN) Study Show Maintenance Therapy is Associated with Improved Renal Function
2. Data Show Rufinamide, an Investigational Adjunctive Treatment for Lennox- Gastaut Syndrome, Reduced Drop Attacks by More Than 40%
3. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
4. Data Presented at AAN Show That Lacosamide Significantly Reduced Pain and was Generally Well Tolerated in Patients With Diabetic Neuropathic Pain
5. Medivations Dimebon(TM) Significantly Improved Daily Function in Alzheimers Disease Patients, Resulting in Reduced Need for Caregiver Assistance
6. Lotrel, a Single-Pill Combination for Treating High Blood Pressure, Reduced Cardiovascular Events by 20% in High-Risk Patients
7. Reduced Lung Capacity Accelerates With Diabetes
8. Perioperative Eloxatin(R)-Based Regimen Significantly Reduced the Risk of Relapse Versus Surgery Alone in Eligible Colorectal Cancer Patients with Initially Resectable Liver Metastases
9. Medivations Dimebon(TM) Stabilizes Behavioral Symptoms in Alzheimers Disease Patients, Resulting in Reduced Caregiver Distress
10. Breast Cancer Treatment Is Reduced to One Week
11. Study Shows That Low-Molecular Weight Heparin (LMWH) was Associated with Reduced Hospital Costs of Venous Thromboembolism (VTE) Treatment Compared with Unfractionated Heparin (UFH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... Jan. 15, 2014  According to Millennium Research Group ... intelligence, the United States ... markets will expand moderately through 2022, with embolization ... particular, increasing interest in drug-eluting beads (DEBs) and ...
(Date:1/15/2014)... YORK , Jan. 15, 2014 ... market research report is available in ... Global Markets and Technologies for Advanced ... Routes of Administration ...
(Date:1/14/2014)... , Jan. 14, 2014 InformEx, North ... sellers of high-value chemistry, will hold the 30 th ... Beach Convention Center from January 21-24. ... attendees from top pharmaceutical, fine chemical and specialty chemical companies ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... Reportlinker.com announces that a new market research report ... Merger and Acquisition Terms and Agreements in ... http://www.reportlinker.com/p0306576/Merger-and-Acquisition-Terms-and-Agreements-in-Pharma-Biotech-and-Diagnostics-4th-edition.html ... analysis of how and why companies enter merger ...
... Oct. 7 Sunridge International (OTC Bulletin Board: ... Trabeculoplasty (PNT) non-invasive treatment for glaucoma and ocular hypertension, ... by Beijing Vision World Trading Co. Ltd. (BVW), in ... patient research studies before gaining regulatory approval by China,s ...
Cached Medicine Technology:Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 2Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 3Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 4Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 5Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 6Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 7Reportlinker Adds Merger and Acquisition Terms and Agreements in Pharma, Biotech and Diagnostics, 4th edition 8Sunridge Advances its PNT Glaucoma Treatment Throughout China 2
(Date:7/9/2014)... innovative tool that captures heretofore hidden ways that cells ... protein that makes breast cancer cells more likely to ... cancer,s spread in part by blocking two other proteins ... suggests these two disease processes could have unexpected ties. ... 10 issue of Nature , points to the ...
(Date:7/9/2014)... in Russia might contribute to HIV transmission and ... researchers from Boston University Schools of Medicine and ... State University, sought to discover the effect police ... cohort of HIV-positive people with lifetime of injection ... police were more likely to share needlesincreasing HIV ...
(Date:7/9/2014)... YORK (July 8, 2014) Researchers from Montefiore ... of Medicine of Yeshiva University will present new ... held July 12 July 17 in Copenhagen, Denmark. ... that could prompt transition from cognitive normality to mild ... the Einstein Aging Study , established in 1980 ...
(Date:7/9/2014)... most important organs in the human body. Its job ... this is its synthesis function and that ... is its detoxification function. Lack of exercise and too ... liver. The resulting diseased cells can lead to inflammations, ... According to the German Liver Foundation, over five million ...
(Date:7/9/2014)... Qubec City, July 9, 2014 A study published ... Yves De Koninck and Robert Bonin, two researchers at ... pain hypersensitivity using a new method that involves rekindling ... discovery could lead to novel means to alleviate chronic ... at Universit Laval and Institut universitaire en sant mentale ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2
... screening to identify lung tumors likely to respond ... drugs as first-line treatment rather than after standard ... Massachusetts General Hospital Cancer Center investigators found that ... for non-small-cell-lung-cancer (NSCLC), additional research is required before ...
... the ... chance to change people,s lives, OTTAWA, May 20 ... for new ways to make the most of their,time, especially ... independent marketing opportunities provided by,Melaleuca, The Wellness Company(R)., One ...
... May 20 Wednesday, May 21, 2008,Easter Seals Greater ... Mary Landrieu and Capital One for,their efforts on behalf ... Awards Benefit will be held at the JW Marriott ... and dinner at 7:00,pm. Gordon Peterson of WJLA TV ...
... per patient , , TUESDAY, May 20 (HealthDay News) ... latent tuberculosis saves time, money and lives, new research ... of four months of Rifampin instead of the current ... health-care system," lead analyst Anne Aspler, of the respiratory ...
... May 20 The retiring baby boomers,have challenged ... Moreover, the multi-generational workforce is challenging,companies across all ... to define a new type of leader., ... new thinking,around leadership models, discover fast-acting tactics and ...
... idiopathic pulmonary fibrosis (IPF) may have a new treatment ... Phase III, double-blind, placebo-controlled clinical trial, the investigators discovered ... progression of IPF, reducing the loss of lung capacity. ... Societys 2008 International Conference in Toronto on Tuesday, May ...
Cached Medicine News:Health News:Determining genetic signature of lung tumors can help guide treatment 2Health News:Determining genetic signature of lung tumors can help guide treatment 3Health News:Lucrative Sales Opportunities Abound With Melaleuca, The Wellness Company(R) 2Health News:New Latent TB Drug Saves Lives, Money 2Health News:Fortune 500s to Convene in Florida, Sharing Insights & Best Practices for Developing Tomorrow's Leaders 2Health News:New treatment gives hope for pulmonary fibrosis patients 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: